Daily Management Review

Pfizer to sell its healthcare business in November: Sources


10/26/2017


As per Pfizer’s Chief Executive, the core reason for this divestiture is to provide a better return for shareholder’s money: its consumer healthcare is worth more outside the group than within.



According to multiple source close to the matter at hand, Pfizer plans on divesting its $15 billion plus consumer healthcare business in November through an auction.
 
Several global companies, including Reckitt Benckiser and GlaxoSmithKline have expressed interest in bidding for its business, which had a turnover of $3.4 billion last year.
 
The prospective sale, which is being led by Centerview Partners, Guggenheim Securities and Morgan Stanley, was first mooted on October 10, when Pfizer said it was considering strategic options for the unit.
 
However, sources say preliminary discussions with interested parties, including Reckitt, have already taken place.
 
Pfizer wants to get the process started before the end of 2017.
 
On Wednesday, Emma Walmsley, GSK’s Chief Executive had confirmed that she would look “carefully” at the business.
 
As per 3 sources familiar with the situation, GSK has hired Citi to represent it in the auction.
 
GSK declined to comment. Citi was not immediately available for comment.
 
As per several sources, other prospective bidders include, Sanofi, Procter & Gamble, Nestle and Johnson & Johnson.
 
Pfizer plans to send out financial information about the consumer unit to prospective buyers in around three weeks time, said one of the sources, who went on to add, the bidding process is expected to heat up early next year and is expected to be sealed around the middle of 2018.
 
As per a source, Pfizer expects to raise at least $20 billion from this divestiture, given the repertoire of brands the business has in its basket including, painkiller Advil, lip balm Chapstick and multivitamins Centrum.
 
In recent year, with consumers growing increasingly health conscious, demand for medication and the consumer health sector has been a fertile ground for deal-makers.
 
As per Ian Read, Pfizer’s Chief Executive, he intends to sell the consumer healthcare business since it isn’t an integral part to the company’s core prescription drug business and might be worth more outside the group.


References:
reuters.com
 







Science & Technology

Porsche, Boeing set to develop flying electric car

Samsung to invest $ 11 billion in new generation displays

US is betting on Nokia and Ericsson to replace Huawei

UPS becomes first to receive full regulatory approval for UAV shipping in USA

NASA orders Lockheed Martin to build spacecraft to fly to the Moon

Hyundai to create joint venture for unmanned vehicles

Bain & Company: E-wallets and cheaper transactions are new payment trends

Is UAV drone industry falling into decay?

UK Scotland Yard employs AI to deal with frauds

US sets to fight robocalls outbreak

World Politics

World & Politics

France: We will take measures to protect our military in Syria

Paralyzed Hong Kong: Protests don't fade

Johnson unveils Brexit compromise deal considering Irish issue

African swine fever at Europe’s borders: time for an embargo?

Saudi Crown Prince Says Khashoggi’s Murder Happened Under His Watch

Will Merkel restore her "Climate Chancellor" image?

Venezuelan opposition to receive $ 52 mln from USA

US And Saudi Threatened By Iranian Commanders In Case Of An Attack On Tehran